Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Dabigatran on Coagulation parameters-an ex Vivo Study

This study has been completed.
Information provided by:
Johann Wolfgang Goethe University Hospital Identifier:
First received: April 27, 2010
Last updated: June 5, 2012
Last verified: April 2010
Dabigatran represent a new class of promising anticoagulation agents. As an oral direct thrombin inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery. This ex vivo study is undertaken to investigate the ex-vivo effects of Pradaxa® on different coagulation parameters.

Effect of Dabigatran in Laboratory Coagulation Parameters

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Effect of Dabigatran on Coagulation Parameters in Patients Undergoing Elective Orthopaedic Surgery

Resource links provided by NLM:

Further study details as provided by Johann Wolfgang Goethe University Hospital:

Estimated Enrollment: 70
Study Start Date: April 2010
Study Completion Date: April 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Detailed Description:
This mono-centric, open-label study is undertaken to validate the effects of Dabigatran on coagulation parameters in plasma samples of 70 patients after hip or knee replacement surgery treated with Dabigatran 150-220 mg/d. Plasma samples are obtained by blood collection before, after 2 hours and after 12-14 hours after Dabigatran dosing in steady state (on 3rd - 5th day).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients after hip or knee replacement surgery treated with Dabigatran 150-220 mg/d

Inclusion Criteria:

  • Age > 18 y

Exclusion Criteria:

  • Hemorrhagic disorder
  • Liver disease
  • Anemia
  • Severe renal impairment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01112202

Johann Wolfgang Goethe University Hospital
Frankfurt, Germany, 60590
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
  More Information

Responsible Party: Prof. Edelgard Lindhoff-Last, Department of Vascular Medicine, University Hospital Frankfurt Identifier: NCT01112202     History of Changes
Other Study ID Numbers: Dabi2010
Study First Received: April 27, 2010
Last Updated: June 5, 2012

Keywords provided by Johann Wolfgang Goethe University Hospital:
direct thrombin inhibitors
Coagulation parameters

Additional relevant MeSH terms:
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants processed this record on April 27, 2017